Conclusion: Numerous interactions between herbal medicines and conventional drugs have been documented. While the significance of many interactions is uncertain, several interactions, particularly those with St John's wort, may have serious clinical consequences.
PubMed 19719333 ↗Kava
The short answer. More people than not who report on Kava say it helped (63% of 224). It is most often used for anxiety: 93% of 196 reports say that improved. It is well studied — 41 meta-analyses on PubMed. The most common complaint is drowsiness.
From 431 mentions in total — the rest didn't say how it went and aren't counted.
What Kava does, according to users
Of the people who reported each effect, the share who said it got better.
2 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 41 meta-analyses on PubMed ↗ · 37 randomized trials ↗
Conclusion: Medicinal herbs may be promising for the treatment of anxiety. However, these results should be considered preliminary because of the unconvincing sample sizes, together with the potential effectiveness of placebos.
PubMed 35378276 ↗Conclusion: There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas.
PubMed 31948424 ↗Conclusion: Based on the current data and clinician input, a range of nutraceuticals and phytoceuticals were given either a supportive recommendation or a provisional recommendation across a range of various psychiatric disorders. However several had only a weak endorsement for potential use; for a few it was not possible to reach a clear recommendation direction, largely due to mixed study findings; while some other agents showed no obvious therapeutic benefit and were clearly not recommended for use. It is the intention of these guidelines to inform psychiatric/medical, and health professional practice
PubMed 35311615 ↗18 human trials on ClinicalTrials.gov test Kava — 7 completed, 3 recruiting now. See all on ClinicalTrials.gov ↗
- Biomarker Changes and Anxiolytic Effects-Phase 2 · Pharmacokinetics · 2023
- A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics · Pharmacokinetics · 2021
- Kavalactones on Sleep and Cortisol in Healthy Special Forces Trainees · Sleep · 2022
Reports to the FDA
Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.
58 reports name a product containing Kava (2004–2026); 32 involved hospitalization or worse. Most often reported:
- Nausea · 18
- Dependence · 10
- Fatigue · 9
- Vomiting · 9
- Diarrhoea · 8
- Rash · 5
A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Not a scheduled substance, but the DEA lists Kava as a drug of concern. DEA fact sheet ↗
7 recalls of products named for Kava. Most recent:
- 2023-12-20 · Class II: Finished product contains kratom (an unapproved food additive) and pH is over 5.0. The process authority letter classified product as acidified and pH… record ↗
- 2022-06-29 · Class II: The microbial test result is found to be out of specification due to high yeast and mold counts. record ↗
- 2016-05-11 · Class III: Pursuant to a consent decree for injunctive relief the recalling firm was ordered to recall all products because they are misbranded, unapproved new drugs… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
LiverTox rates Kava A — a well-established cause of liver injury (more than 50 published cases). LiverTox entry ↗
“Various kava products have been linked to rare cases of liver injury, some of which have been serious or even fatal. The first reported cases involved medicinal or dietary supplement products that had been extracted with alcohol or acetone, but other cases have involved kava beverages prepared with water.” NCCIH ↗
The EMA reviewed Kava-kava and did not issue a monograph (public statement). EMA ↗
NIH has funded 6 research projects with Kava in the title, $3,135,823 in total (2000–2026). NIH RePORTER ↗
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I felt insanely relaxed, any anxiety was dropped to 0, and I could think more clearly.”
“Kava has a definite affect on me, but didn’t budge any of my sleep scores.”
“The only stuff I actually FEEL are anxiolytics (eg kava) or stimulants (eg caffeine, nicotine and stronger stuff.)”
“I use it once or twice a week, and I feel that it really helps alleviate my anxiety.”
Kava compared
Other options for anxiety
Sources
- User reports: 431 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA recalls ↗
- US DEA ↗
- LiverTox (NIH) ↗
- NCCIH (NIH) ↗
- NIH RePORTER ↗
- European Medicines Agency ↗
- US Food and Drug Administration: CAERS adverse-event reports ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate